An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and...
This trial is investigating the efficacy and tolerability of afuresertib [GSK-2110183; GlaxoSmithKline] combined with ofatumumab [Arzerra] in patients withhttp://adisinsight.springer.com/trials/700213560
Clinical Trial: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and...
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell ... Clinical trial focusing on CD20 positive lymphoma and mantle cell lymphoma. ... Clinical Trial: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and ... Clinical Trial: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and ...https://www.oncologynurseadvisor.com/lymphoma-clinical-trials/clinical-trial-rituximab-maintenance-therapy-in-aggressive-cd20-cluster-of-differentiation-antigen-20-positive-lymphoma-and-mantle-cell-lymphoma/article/312453/
Tositumomab - DrugBank
Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues ... Binds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement- ... Tositumomab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on ,90% of B-cell non-Hodgkin's ... Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues ...https://www.drugbank.ca/drugs/DB00081
Tissue expression of MS4A1 - Summary - The Human Protein Atlas
CD20, MS4A2) expression in human tissue. Membranous and cytoplasmic expression in subsets of immune cells. ... B-lymphocyte antigen CD20 A0A024R507 [Target identity:100%; Query identity:100%]. Membrane-spanning 4-domains, subfamily A, ... B-lymphocyte antigen CD20 A0A024R507 [Target identity:100%; Query identity:100%]. Membrane-spanning 4-domains, subfamily A, ... B-lymphocyte antigen CD20 A0A024R507 [Target identity:100%; Query identity:100%]. Membrane-spanning 4-domains, subfamily A, ...http://www.proteinatlas.org/ENSG00000156738-MS4A1/tissue
Ofatumumab - DrugBank
Ofatumumab binds specifically to both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is ... The Fab domain of ofatumumab binds to the CD20 molecule and the Fc domain mediates immune effector functions to result in B- ... Ofatumumab is a human monoclonal antibody for the CD20 protein. ... Details1. B-lymphocyte antigen CD20. Kind. Protein. Organism. ... The CD20 molecule is expressed on normal B lymphocytes (pre-B- to mature B-lymphocyte) and on B-cell CLL. The CD20 molecule is ...https://www.drugbank.ca/drugs/DB06650
Brevet US20030087245 - Uses of PBH1 in the diagnosis and therapeutic treatment of prostate cancer - Google Brevets
Examples of such antigens include Her2/neu and the B-cell antigen CD20. Humanized monoclonal antibodies directed to Her2/neu ( ... CD20, the target of Rituximab in non-Hodgekin's lymphoma (Maloney et al., Blood 90:2188-2195 (1997); Leget and Czuczman, Curr. ... Antigens suitable for immunotherapeutic strategies should be highly expressed in cancer tissues and ideally not expressed in ... As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which ...http://www.google.fr/patents/US20030087245?hl=fr
Rheumatoid Arthritis Drugs Market Worth $30.4 Billion by 2025: Grand View Research, Inc.
CD20 antigen. *TNF-? antagonists. *Rheumatoid Arthritis Therapeutics Sales Channel Outlook (Revenue, USD Million, 2014 - 2025) ...https://www.medindia.net/health-press-release/Rheumatoid-Arthritis-Drugs-Market-Worth-304-Billion-by-2025-Grand-View-Research-Inc-359045-1.htm
Rituximab to Treat Neuropathy With Anti-MAG Antibodies - Full Text View - ClinicalTrials.gov
Rituximab is a monoclonal antibody specific for the common B cell antigen CD20. Its administration depletes pre-B and mature B ... fine specificities of the IgM antibodies to various glycoconjugates or differences in the affinity binding to various antigens ...https://clinicaltrials.gov/show/NCT00050245
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV...
Histologically confirmed DLBCL expressing CD20 antigen; patients with transformed lymphoma are excluded; in this regard, ... CD20 Positive Drug: Cyclophosphamide Drug: Doxorubicin Hydrochloride Other: Laboratory Biomarker Analysis Drug: Lenalidomide ...https://clinicaltrials.gov/ct2/show/NCT01856192
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris - Full Text View - ClinicalTrials.gov
human CD20 antigen. subcutaneous. Pemphigus vulgaris. Phase 3. monoclonal antibody. ofatumumab. PV. rare disease. ... Ofatumumab is a novel monoclonal antibody (mAb) that specifically binds to the human CD20 antigen, which is expressed only in B ... Positive test for hepatitis B surface antigen (HBsAg). For HBsAg negative, but hepatitis B core antibody (anti-HBc/HBcAb ...https://clinicaltrials.gov/ct2/show/NCT01920477?term=pemphigus&recr=Open&lup_s=05%2F23%2F2013&lup_d=180
Anti-CD20 and CD22 Therapy Is Effective in Non-Hodgkin Lymphoma | Cancer Discovery
Rituximab is a monoclonal antibody approved for treatment of non-Hodgkin lymphomas that targets CD20, an antigen expressed by ... Mechanism: Rituximab and inotuzumab ozogamicin target the B-cell antigens CD20 and CD22, respectively. ... Anti-CD20 and CD22 Therapy Is Effective in Non-Hodgkin Lymphoma Message Subject (Your Name) has forwarded a page to you from ... Another B-cell antigen, CD22, which is expressed by the vast majority of B-cell cancers but not by lymphocyte precursors or ...http://cancerdiscovery.aacrjournals.org/content/early/2013/01/15/2159-8290.CD-RW2013-014
Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia - Tabular View -...
Rituximab is a monoclonal antibody that is designed to work against cells that express the antigen CD20. In addition, some ... Patients must have a related, genotypically human leukocyte antigens (HLA) identical donor, or they must have a related or ...https://clinicaltrials.gov/ct2/show/record/NCT00427791
MS4A10 Gene - GeneCards | M4A10 Protein | M4A10 Antibody
Suggested Antigen Peptide Sequences for MS4A10 Gene. GenScript: Design optimal peptide antigens:. *CD20 antigen-like 7 (M4A10_ ... Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human ...http://www.genecards.org/cgi-bin/carddisp.pl?gene=MS4A10
Antibodies | Free Full-Text | Role and Redirection of IgE against Cancer | HTML
The same group produced a murine/human chimeric IgE antibody specific for the human B cell antigen CD20 . The anti-hCD20 ... CD23a is expressed on antigen-activated B cells and is involved in IgE antibody-dependent antigen endocytosis, processing and ... 2.4.4. Antigen-Presenting Cells. APC such as B lymphocytes, monocytes, Langerhans cells and DC in tumor infiltrates express ... The prostate-specific antigen (PSA) is a promising target for PCa immunotherapy because of its organ specific production. In ...http://mdpi.com/2073-4468/2/2/371/htm
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non...
Institutional flow cytometry or immunohistochemistry must confirm CD20 antigen expression. *Low or intermediate risk by ... hepatitis B surface antigen positive [HBsAg +]) are eligible if they are closely monitored for evidence of active HBV infection ...https://clinicaltrials.gov/show/NCT01145495
Anti-Human CD20 F(ab) Stable Cell Line-CHO CSC-P0312 - Creative BioMart
... which has been transfected with an anti-human CD20 F(ab) gene to allow expression of the F(ab). It is an example of a cell line ... CHO-Anti-Human CD20 F(ab) stable cell line is clonally-derived from a CHO cell line, ... B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1 ... Anti-Human CD20 F(ab) Stable Cell Line-CHO. Download Datasheet See All MS4A1 Products. Bring this labeled protein directly to ...https://www.creativebiomart.net/description_145352_309.htm
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Relapsed...
Evidence of CD20 antigen expression in tumor tissue. - Bidimensionally measurable disease. - No progressive disease in a field ...http://www.knowcancer.com/cancer-trials/NCT00006695/
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Rituximab and GA101 both target the CD20 antigen. The CD20 antigen is located on the surface. of normal and malignant B-cell ... CD20 is not on hematopoietic stem cells, nor is it expressed in any great extent on other. normal body tissues.. Studies in ... cell-death related to an elbow hinge amino acid exchange and Type II binding of the CD20. epitope. The safety of GA101 in NHL ... rheumatoid arthritis) or prior use of an anti-CD20 antibody.. - No prior use of any monoclonal antibody within 3 months of ...http://www.knowcancer.com/cancer-trials/NCT01889797/
The Tumor Microenvironment Controls Primary Effusion Lymphoma Growth in Vivo | Cancer Research
Hence, PELs were initially called BCBLs (34) . Because PELs generally do not express B cell-lineage antigens (CD20; Ref. 36 ), ... Proliferating cell nuclear antigen was detected using rabbit antiproliferating cell nuclear antigen antibody (FL261; Santa Cruz ... Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. J Hum Virol, 1: 19-29, 1997. ... Kedes DH, Lagunoff M, Renne R, Ganem D. Identification of the gene encoding the major latency-associated nuclear antigen of the ...http://cancerres.aacrjournals.org/content/64/14/4790.long
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP...
Patients must have evidence that their tumor tissue expresses the CD20 antigen. ...https://clinicaltrials.gov/ct2/show/NCT00022932
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab -...
Patients must have evidence that their tumor tissue expresses the CD20 antigen. Immunoperoxidase stains of paraffin-embedded ... positive reactivity with Anti-B1 Antibody or evidence of CD20 positivity by flow cytometry are acceptable evidence of CD20 ...https://clinicaltrials.gov/ct2/show/NCT00996593?cond=%22Lymphoma%2C+Non-Hodgkin%22&rank=10
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement - Full Text...
Patients must have evidence that their tumor tissue expresses the CD20 antigen. ...https://clinicaltrials.gov/ct2/show/NCT00022906
anal canal squamous dysplasia 2005:2010[pubdate] *count=100 - BioMedLib™ search engine
Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Antimetabolites, Antineoplastic; 0 / ... Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers; 0 / Ki-67 Antigen; 0 / Vascular Endothelial ... Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / ... Antigens, CD / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Anus Diseases / pathology. Anus Diseases ...http://www.bmlsearch.com/?kwr=anal+canal+squamous+dysplasia+2005:2010%5Bpubdate%5D&cxts=100&stmp=b0
adult anaplastic oligoastrocytoma 2005:2010[pubdate] *count=100 - BioMedLib™ search engine
Antigens, CD20 / metabolism. Antigens, CD45 / metabolism. Cell Count / methods. Child. Child, Preschool. Female. Follow-Up ... Chemical-registry-number] 0 / Actins; 0 / Antigens, CD20; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / ... Ki-67 Antigen / metabolism. Male. Neurofilament Proteins / metabolism. Synaptophysin / metabolism. Vimentin / metabolism ...http://www.bmlsearch.com/?kwr=adult+anaplastic+oligoastrocytoma+2005:2010%5Bpubdate%5D&cxts=100&stmp=b0
B-cell depletion - A frontier in monoclonal antibodies for multiple sclerosis<...
TY - JOUR. T1 - B-cell depletion - A frontier in monoclonal antibodies for multiple sclerosis. AU - Calabresi,Peter A.. PY - 2017/1/19. Y1 - 2017/1/19. UR - http://www.scopus.com/inward/record.url?scp=85010952470&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85010952470&partnerID=8YFLogxK. U2 - 10.1056/NEJMe1614717. DO - 10.1056/NEJMe1614717. M3 - Editorial. VL - 376. SP - 280. EP - 282. JO - New England Journal of Medicine. T2 - New England Journal of Medicine. JF - New England Journal of Medicine. SN - 0028-4793. IS - 3. ER - ...https://jhu.pure.elsevier.com/en/publications/b-cell-depletion-a-frontier-in-monoclonal-antibodies-for-multiple
Download our free solidary book to support research on VHL disease